Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors

Sponsor
Mateon Therapeutics
Study ID
NCT00395434
Phase
PHASE1
Status
Completed

Conditions

  • Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to determine the safety and tolerability of three dose levels of combretastatin A4 phosphate (CA4P) given intravenously (IV) in combination with bevacizumab every 14 days in patients with advanced solid tumors. The maximum tolerated dose will be defined if it is at one of the three dose levels under study.

Key Dates

First listed
Nov 2, 2006
Start date
Sep 30, 2006
Status verified
Oct 2011
Primary completion
Jan 31, 2007
Completion
Jan 31, 2007

Study Design

Enrollment
20 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Primary Outcome Measure

safety and tolerability of the combination therapy assessed by analysis of adverse events

Related Studies